Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia. Show more
Location: Australia Square, L 12 95 Pitt St, Sydney, NSW, 2000, Australia | Website: https://www.immutep.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
237.3M
52 Wk Range
$1.32 - $2.72
Previous Close
$1.63
Open
$1.66
Volume
143,435
Day Range
$1.59 - $1.67
Enterprise Value
144.2M
Cash
129.7M
Avg Qtr Burn
-15.51M
Insider Ownership
0.01%
Institutional Own.
1.91%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) + Keytruda Details Non-small cell lung carcinoma (1L NSCLC) | Phase 3 Data readout | |
Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) Details Metastatic breast cancer | Phase 2/3 Data readout | |
Eftilagimod Alpha (LAG-3lg or IMP321) + Keytruda Details Head and neck squamous cell carcinoma (1L HNSCC) | Phase 2b Update | |
Eftilagimod Alpha + Pembrolizumab Details Cancer, Soft tissue sarcoma | Phase 2 Update | |
Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) and avelumab Details Non-small cell lung carcinoma (1L NSCLC) | Phase 1 Data readout | |
IMP761 (LAG-3 agonist) Details Autoimmune disease | Phase 1 Data readout | |
Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) and avelumab Details Solid tumor/s, Cancer, Urothelial cancer | Phase 1 Update | |
IMP761 (Agonist AB) Details COVID-19 | Failed Discontinued |